Glucose Metabolism Modification Induced by Radioligand Therapy with [¹⁷⁷Lu]Lu/[⁹⁰Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial

[¹⁸F]F-FDG (FDG) PET is emerging as a relevant diagnostic and prognostic tool in neuroendocrine neoplasms (NENs), as a simultaneous decrease in [⁶⁸Ga]Ga-DOTA peptides and increase in FDG uptake (the “flip-flop” phenomenon) occurs during the natural history of these tumors. The...

Description complète

Détails bibliographiques

Auteurs principaux:	Luca Urso, Stefano Panareo, Angelo Castello, Maria Rosaria Ambrosio, Maria Chiara Zatelli, Matteo Caracciolo, Eugenia Tonini, Giorgia Valpiani, Alessandra Boschi, Licia Uccelli, Corrado Cittanti, Mirco Bartolomei
Format:	Artigo
Langue:	Inglês
Publié:	MDPI AG 2022-09-01
Collection:	Pharmaceutics
Sujets:	neuroendocrine neoplasms NEN NET radioligand therapy RLT peptide receptor radionuclide therapy
Accès en ligne:	https://www.mdpi.com/1999-4923/14/10/2009
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!